Studies in patients with renal cell carcinoma have shown that mutations in TSC1/2 and mTOR are associated with rapalog resistance, although these mutations are not present in most patients, supporting the potential of targeting Ephexin1 in overcoming resistance68. Here, MTOR is linked to renal cell carcinoma.